Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$12.46 - $29.95 $1.11 Million - $2.66 Million
-88,692 Reduced 4.62%
1,829,215 $54.2 Million
Q3 2023

Nov 14, 2023

SELL
$14.09 - $19.87 $1.13 Million - $1.59 Million
-79,893 Reduced 4.0%
1,917,907 $30.4 Million
Q2 2023

Aug 14, 2023

BUY
$3.75 - $20.05 $7.49 Million - $40.1 Million
1,997,800 New
1,997,800 $37.7 Million

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Avidity Partners Management LP Portfolio

Follow Avidity Partners Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Avidity Partners Management LP with notifications on news.